Abstract | OBJECTIVE: METHODS: RESULTS: The seroconversion rate of HBV- DNA and HBeAg in the treated group was 43.47% and 43.47% respectively, which was obviously better than those in the control group respectively (P < 0.05), the quantity of HBV- DNA decreased after treatment from 10(6.83 +/- 1.27) copy/ml to 10(3.35 +/- 3.08) copy/ml. Among them, in patient with HBeAg negative conversion, the pretreatment quantity of HBV- DNA was 10(6.30 +/- 1.42) copy/ml, while in those with no HBeAg negative conversion, it was 10(7.23 +/- 1.23) copy/ml, the difference was significant. CONCLUSION:
|
Authors | Yan-xi Chen, Bai-yuan Mao, Jian-hua Jiang |
Journal | Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
(Zhongguo Zhong Xi Yi Jie He Za Zhi)
Vol. 22
Issue 5
Pg. 335-6
(May 2002)
ISSN: 1003-5370 [Print] China |
PMID | 12584828
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Alkaloids
- Antiviral Agents
- DNA, Viral
- Hepatitis B e Antigens
- Quinolizines
- oxymatrine
|
Topics |
- Adult
- Alkaloids
(therapeutic use)
- Antiviral Agents
(therapeutic use)
- DNA, Viral
(blood)
- Female
- Hepatitis B e Antigens
(blood)
- Hepatitis B virus
(genetics, isolation & purification)
- Hepatitis B, Chronic
(drug therapy, virology)
- Humans
- Injections, Intramuscular
- Male
- Middle Aged
- Polymerase Chain Reaction
- Quinolizines
|